The term 'kynurenines' is used widely to describe the metabolites of the kynurenine pathway of tryptophan degradation. This catabolic cascade, which accounts for approximately 90% of tryptophan metabolism in mammals, gives rise to two compounds with well documented neuroactive properties, quinolinic acid (QUIN) and kynurenic acid (KYNA).
Neuroactive kynurenines
The term 'kynurenines' is used widely to describe the metabolites of the kynurenine pathway of tryptophan degradation. This catabolic cascade, which accounts for approximately 90% of tryptophan metabolism in mammals, gives rise to two compounds with well documented neuroactive properties, quinolinic acid (QUIN) and kynurenic acid (KYNA).
As originally discovered by Stone and Perkins [ 13, QUIN is a selective agonist at the N-methyl-1)-aspartate (NMDA) receptor. QUIN has been speculatively linked to the aetiology of several brain diseases, and has also been used widely to provide
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animal models for those diseases. In particular, intrastriatal QUIN injections in experimental animals produce lesions which closely resemble the striatal neuropathology of Huntington's disease [2, 31, whereas intrahippocampal application of QUIN leads to convulsions and associated lesions which are highly reminiscent of those seen in temporal lobe epilepsy [4] . QUIN also causes circumscribed 'axon-sparing' lesions in several other brain regions and is therefore frequently used as the excitotoxin of choice in neurobiological studies [5] . Equally important but not yet sufficiently explored is the potential role of QUIN as an endogenous modulator of the NMDA receptor. Although QUINs affinity to the receptor is relatively low, and its endogenous concentration in the normal mammalian brain is only between 100 nM and 1 p M [6], recent anatomical studies have suggested that the local concentration of QUIN at the synapse may be sufficiently high to influence receptor function.
QUIN could therefore conceivably participate in several physiological processes in which NMDA receptors are now known to play a central role [7] . Again first recognized in Stone's laboratory, KYNA is a broad spectrum antagonist of excitatory amino acid receptors [8] . KYNA was later shown to have a particularly high affinity to the glycine site of the NMDA receptor complex [9] , and is thus likely to act preferentially as an NMDA receptor antagonist. Like QUIN, KYNA has also been identified as a natural brain constituent. Its concentration in brain tissue varies substantially between species, ranging from approximately 6 nM in mice [ 101 to approximately 1 ,LAM in humans [ 111. In line with its ability to antagonize excitatory amino acid receptor function, KYNA has been shown to possess anticonvulsant and neuroprotective properties in several relevant animal models [ 121. It is therefore an endogenous anti-excitotoxin, and can be envisioned to counteract the effects of several naturally occurring excitatory transmitters or transmitter candidates, such as glutamate, aspartate, sulphur-containing amino acids or QUIN. Like QUIN, KYNA, too, may play a modulatory role in excitatory neurotransmission, although it remains to be demonstrated that its concentration in the synapse is adequate to affect receptor function to a significant degree. Conceivably, a decrease in KYNA function may therefore result in overexcitation due to an imbalance between KYNA and one or more endogenous excitants. This, in turn, could have physiological consequences or, if extended for a long period of time, may result in excitotoxic pathophysiology Kynurenines other than QUIN and KYNA have not been unequivocally shown to possess neuroactive properties, but species differences may exist. Thus, kynurenine, in the periphery the parent compound of both QUIN and KYNA (Figure l) , causes convulsions after intraventricular injections in mice [ 131, but not in rats (R. Schwarcz, unpublished observation). There is also evidence from studies in cell culture that 3-hydroxykynurenine, in the periphery a metabolite of kynurenine en route to QUIN (Figure l) , is neurotoxic [14] . This finding has not as yet been duplicated in vivo, however, and 3-hydroxykynurenine toxicity seems to be related to the generation of free radicals rather than a direct action on excitatory amino acid receptors [15] . Thus, 3-hydroxykynurenine may play a role in brain pathology without functioning as a neuroactive brain metabolite under physiological conditions.
[121. 
Biosynthesis and degradation of brain kynurenines: metabolic enzymes
The discovery of neuroactive kynurenines has stimulated the study of the cerebral metabolism of QUIN and KYNA. Because of their polar structure and the lack of carrier mechanisms [16] , neither QUIN nor KYNA can normally enter the brain. They are therefore likely to be synthesized in the brain itself. Research focussed originally on metabolic enzymes which were directly responsible for the synthesis and catabolism of these two kynurenines. In addition, since kynurenine, using the large neutral amino acid transporter, can readily penetrate the blood-brain barrier [ 16, 171, attention was also paid to the neurochemical characteristics of this suspected parent compound of both QUIN and KYNA.
Virtually all research strategies relied heavily on knowledge which had accumulated from work on peripheral organs over the past half century. Thus, all elements of the kynurenine pathway had been elaborated (see Figure l) , and several metabolic enzymes had been thoroughly characterized. T o date, however, the functional integrity of the Volume 
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kynurenine pathway in the mammalian brain, in particular a quantitatively significant conversion of tryptophan to either QUIN or KYNA, has not been documented. Thus, while systemic administration of either tryptophan [ 18, 191 or kynurenine [19, 201 results in an increase in brain QUIN and KYNA concentrations, it remains unclear which portion of the metabolic cascade takes place in the brain itself.
In spite of the apparent differences between the overall efficiency of the kynurenine pathway in periphery and brain, several metabolic enzymes have been identified and at least partly characterized in cerebral tissue. This was reviewed in detail recently [6] and will only be highlighted here.
3-Hydroxyanthranilic acid oxygenase (3HAO) and quinolinic acid phosphoribosyltransferase (QPRT), the anabolic and degradative enzymes, respectively, of QUIN are present in the rat and human brain and have biochemical and pharmacological characteristics which closely resemble those of the peripheral enzymes. Notably, the V,,,,, value of 3HA0 is approximately 100 times higher than that of QPRT, suggesting that QPRT may function as a rate-limiting step in cerebral QUIN metabolism. Both enzymes were purified to homogeneity, and antibodies against pure 3HA0 and QPRT were used for immunocytochemical studies in rat brain. Both enzymes were found to be preferentially associated with astrocytes, in agreement with biochemical studies, which showed increases in both 3HA0 and QPRT activity following experimentally induced neuronal lesions [21] . Recent studies have extended the analysis to the ultrastructural level and revealed that 3HAO-immunoreactivity (but interestingly not QPRT-immunoreactivity) is contained in thin and highly ramified astrocytic processes which frequently engulf excitatory (probably mostly glutamatergic) synapses [22] . This indicates that newly produced QUIN, upon release into the extracellular milieu, is likely to be in an excellent position to influence NMDA receptor function.
The first enzyme of the kynurenine pathway (Figure l) , indoleamine-2,3-dioxygenase, is present in the brain in very small quantities [23] . Kynurenine-3-hydroxylase and kynureninase, the two enzymes catalysing kynurenine degradation to 3-hydroxykynurenine and 3-hydroxyanthranilic acid, respectively, also show very low activity in the brain. In fact, all of these enzyme activities are difficult to measure in the (rat) brain using conventional methodologies [24, 2.51 . It remains to be seen if alternative enzymic mechanisms, such as the 3-hydroxylation of anthranilic acid to yield the QUIN precursor 3-hydroxyanthranilic acid, play a role in the synthesis of QUIN in the brain [26] .
The enzymic conversion of kynurenine to KYNA by kynurenine aminotransferase (KAT) is carried out quite efficiently in the brain. In the rat, only a single KAT enzyme is capable of producing KYNA at physiological (low micromolar) kynurenine concentrations [27] . Antibodies raised against pure rat KAT were used for immunohistochemistry and, as in the case of 3HA0 and QPRT, revealed a preferential localization of the enzyme in astrocytes "231. Again, biochemical studies in lesioned brain tissue corroborated the immunohistochemical data [27] . Subsequent analysis at the ultrastructural level, too, paralleled the results obtained with the two QUIN-metabolic enzymes. Thus, KAT-containing astrocytic processes are often seen in the immediate vicinity of asymmetric excitatory synapses [ 121.
Although double-labelling experiments with KATand 3HAO-or QPRT-antibodies have not yet been possible for methodological reasons, it is therefore fair to assume that at least some astrocytes can synthesize both QUIN and KYNA. It follows that an anatomical basis may indeed exist for the long purported thesis that the balance between QUIN and KYNA production is a critical element in the role of both metabolites as modulators of excitatory amino acid receptor function.
The enzymic machinery for KYNA production in the human brain is more complex since two distinct KATs with different catalytic properties exist [29] . Because neither of the two proteins closely resembles rat brain KAT, it is currently difficult to predict if and to what extent each of the two enzymes bears responsibility for KYNA production under physiological conditions or in various pathological situations.
Although KYNA can be enzymically degraded by micro-organisms [ 301, no catabolic enzyme for KYNA has yet been found in mammalian tissues, including the brain [31] . It therefore seems that KYNA, upon liberation into the extracellular compartment, diffuses out of the brain, and that this probenecid-sensitive process [ 321, rather than enzymic degradation or re-uptake, terminates KYNA action in the brain.
Regulation of kynureninergic function in the brain
In view of the possible consequences of changes in the extracellular concentrations of QUIN and KYNA in the brain, the study of regulatory processes soon became a primary focus of kynurenine research. Most studies were conducted in the rat in vivo, using either microdialysis and subsequent metabolite measurements, or behavioral manifestations as an assessment tool. In addition, some work was performed in brain slices, which permit the study of ion substitutions and the examination of both intra-and extracellular compartments.
In these intact systems, neither QUIN nor KYNA were found to be released upon depolarization. Moreover, no mechanisms are in place to rapidly remove the two kynurenines from the extracellular space [ 5, 3 11 . These characteristics, together with the preferential localization of the biosynthetic enzymes in astrocytes, argue strongly against neurotransmitter roles for QUIN or KYNA. Both compounds should therefore be regarded as potential neuromodulators whose roles in excitatory neurotransmission remain to be elucidated.
Upon entry into the brain, kynurenine is rapidly transported into astrocytes by a Na+-independent concentrative process [ 331. Because of the absence of significant kynurenine 3-hydroxylase and kynureninase activities, newly accumulated kynurenine is not converted to QUIN, but is either stored or slowly transaminated by KAT to form KYNA, which in turn rapidly exits the cell [34] . Under depolarizing conditions (for example in the presence of veratridine), extracellular KYNA levels decrease [35] . These effects of a depolarizing milieu are brain-specific. The action of veratridine appears to involve the neuronal release of a compound, conceivably glutamate, which in turn affects glial KYNA production and function [ 35 1. These studies have led to the somewht surprising conclusion that the levels of extracellular KYNA, a neuro-inhibitory compound, are lowered in situations where a compensatory increase would be intuitively expected. A decrease in KYNA tone could augment the effects of depolarization and possibly even contribute to the precipitation of excitotoxic phenomena. In this context, it is noteworthy that compounds which inhibit KAT activity and reduce the extracellular levels of KYNA in the brain produce pronounced excitotoxic lesions upon intracerebral injection [ 3 6-3 HI. While brain KYNA levels are clearly responsive to the systemic administration of kynurenine, it is difficult to precipitate behavioral changes or to demonstrate pharmacological effects which can be traced to newly synthesized KYNA [39] . Using intracerebral injections of large amounts of kynurenine, however, anticonvulsant effects have recently been demonstrated in rats [40] .
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The dynamics and regulation of QUIN function in the brain are not well understood. Work in brain slices suggests that anthranilic acid rather than 3-hydroxykynurenine serves as the preferential bioprecursor or 3-hydroxyanthranilic acid, which in turn is converted to QUIN [26] (Figure 1 ). The source of brain anthranilic acid is currently unclear, as is the cellular localization of its hydroxylation. Notably, the incorporation of anthranilic acid into QUIN in the brain has not as yet been successfully accomplished [41] so that the question of the preferential biosynthetic route of brain QUIN under physiological conditions must be considered unresolved at present.
Unlike newly synthesized KYNA, QUIN is retained by brain tissue to a significant extent following de novo production from 3-hydroxyanthranilic acid [42] . Also in contrast to KYNA, no experimental conditions have yet been found to influence the liberation of QUIN into the extracellular compartment. However, astrocytes, which are likely to produce most if not all brain QUIN under physiological conditions, appear to have a limited capacity to retain QUIN. Thus, extracellular QUIN concentrations are greatly increased in experimental situations where 3HA0 exceeds its normal activity [42] . This limited ability of glial cells to either down-regulate 3HA0 or to successfully adapt to an increased requirement for QUIN retention is of potential importance in situations of brain injury. In lesioned tissue, 3HA0 activity consistently shows large increases, and it is possible that increased concentrations of extracellular QUIN constitute a contributing factor to pathophysiological processes [211.
Kynurenines and brain diseases: facts and hypotheses
A comprehensive discussion of the possible role of kynurenines in brain diseases is beyond the scope of this communication (see [43] for a recent review). Only a brief attempt will be made, therefore, to evaluate whether the currently available data from pathological human specimens and relevant animal models support the notion that kynurenines participate in the pathogenesis of neurodegenerative, neuroviral and seizure disorders.
There can be little doubt that the levels and cerebral disposition of QUIN and KYNA change in response to experimentally induced neuronal loss in several human neurodegenerative diseases and in the course of inflammatory conditions in both animals and humans. In most cases, QUIN levels increase, probably due to substantial increases in the activity of one or more enzymes of the kynurenine pathway. Often, astrocytic proliferation, and hence increases in astrocytic 3HA0 activity, appears to be responsible for the elevation in QUIN production [Z 13, but reactive resident microglia or the infiltration of macrophages, which are able to convert tryptophan to QUIN [44] , may play a role in some instances. Thus, in addition to 3HA0, indoleamine-Z,3-dioxygenase, a y-interferoninducible enzyme with very low activity in the normal brain, may be responsible for elevated brain QUIN levels in neuroviral diseases [23] . QPRT activity, too, increases in some pathological situations, but this is quantitatively of minor significance given the low basal activity of QUINs degradative enzyme [Z 11. Finally, hyperphysiological brain QUIN levels could also be a consequence of an enhanced penetration of QUIN or any of its bioprecursors through the blood-brain barrier, which is known to be compromised in cerebrovascular and other neurological diseases.
The fate of brain KYNA under pathological conditions has not yet been examined in great detail. However, all currently available data, again obtained from both animals and humans, indicate that changes in brain KYNA do occur but are less dramatic and at times qualitatively different from those of QUIN [IZ, 43, 45, 461 . Variations in the activity of its biosynthetic enzyme, KAT, or altered penetration of circulating KYNA into the brain, are probably primarily responsible for these changes.
The changes in brain QUIN and KYNA in pathological tissue have generated a number of intriguing questions. First, it has not been established in any instance that a dysfunctional disposition of endogenous QUIN or KYNA can actually cause acute or chronic clinical symptoms. Second, it has not even been clarified if changes in QUIN or KYNA metabolism which occur as a consequence of primary pathogenic insults, participate in any way in a pathological process. In this respect, the possibility that the increase in 3HA0 activity in response to a lesion could result in increased amounts of QUIN, which in turn could cause further neuronal damage, is particularly interesting since this may contribute to the process of slowly progressing neurodegenerative diseases. Third, the respective roles of blood-derived and brain-derived kynurenines clearly needs to be carefully evaluated. In this regard, it is also important to remember that as yet unidentified blood-borne factors may penetrate a dysfunctional blood-brain barrier and influence the action of the neuroactive kynurenines.
Finally, in addition to these fundamental issues, the possible importance of the much debated balance between QUIN and KYNA needs to be explored in detail. Assuming that fluctuations in brain QUIN or KYNA can indeed have pathological consequences, the question certainly arises of whether selective changes in one or the other metabolite can cause distinct pathologies. This cannot be adequately evaluated without specific experimental tools. T o this end, pharmacological agents which are capable of selectively interfering with either QUIN or KYNA function in the brain are currently being developed. There can be little doubt that these compounds will prove instrumental for testing several of the provocative and exciting hypotheses which have emanated from studies in animals and post-mortem human tissue. Notably, because of their ability to normalize a dysfunction of brain QUIN and/or KYNA, some of these compounds could also be of therapeutic value in brain disorders which can be traced to abnormalities in the function of brain kynurenines [12, 431.
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